Fig 1.
A photograph taken by one of the patients showing a washed tablet remnant of nevirapine extended-release collected from stools.
Table 1.
Comparisons of baseline clinical characteristics of HIV-1-infected patients who noticed and those who did not notice tablet remnants of nevirapine extended-release (NVP-XR) in stools.
Table 2.
Frequency of noticing nevirapine extended-release (NVP-XR) tablet remnants and comparisons of virological and immunological outcomes of HIV-1-infected patients with and without noticing tablet remnants of NVP XR in stools.
Fig 2.
Plasma concentrations of nevirapine 12 hours (C12) and 24 hours (C24) following the previous dosing of nevirapine extended-release in patients noticing and those not noticing tablet remnants in stools.
(Numbers in box plots indicate the median, interquartile range, maximum and minimum values).
Table 3.
Comparisons of clinical characteristics and virological and immunological outcomes of HIV-1-infected patients with and without noticing tablet remnants of nevirapine extended-release (NVP-XR) in stools, who underwent therapeutic drug monitoring of plasma concentration of nevirapine.